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Abstract
Objective
Urinary hormonal markers may assist in increasing the efficacy of Fertility Awareness Based Methods
(FABM). This study uses urinary pregnanediol-3a-glucuronide (PDG) testing to more accurately identify
the infertile phase of the menstrual cycle in the setting of FABM.

Methods
Secondary analysis of an observational and simulation study, multicentre, European study. The study
includes 107 women and tracks daily first morning urine (FMU), observed the changes in cervical
mucus discharge, and ultrasonography to identify the day of ovulation over 326 menstrual cycles. The
following three scenarios were tested: (A) use of the daily pregnandiol-3a-glucuronide (PDG) test alone;
(B) use of the PDG test after the first positive urine luteinizing hormone (LH) kit result; (C) use of the
PDG test after the disappearance of fertile type mucus. Two models were used: (1) one day of PDG
positivity; or (2) waiting for three days of PDG positivity before declaring infertility.

Results
After the first positivity of a LH test or the end of fertile mucus, three consecutive days of PDG testing
over a threshold of 5 μg/mL resulted in a 100% specificity for ovulation confirmation. They were
respectively associated an identification of an average of 6.1 and 7.6 recognized infertile days.

Conclusions
The results demonstrate a clinical scenario with 100% specificity for ovulation confirmation and provide
the theoretical background for a future development of a competitive lateral flow assay for the detection
of PDG in the urine.

Graphical abstract
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1. Introduction
Since the mid-20th century, urinary hormone assays have been proposed to help identify the fertile
phase of the menstrual cycle [1], [2]. These assays can be used by women wishing to postpone
pregnancy by using Fertility Awareness Based Methods (FABM). Three urinary hormonal testing
methods have long been proposed in scientific literature to help identify the ovulatory period: oestrone3-glucuronide (E1G), pregnanediol-3a-glucuronide (PDG), and luteinizing hormone (LH) [3], [4]. In
addition to urinary markers, cervical mucus is one of the most widely used biological markers for selfestimating the beginning and end of the fertile phase in a menstrual cycle [5], [6], [7]. Furthermore, two
clinical indicators of ovulation are broadly known, the mucus peak symptom [6], [8], [9], [10], [11] and the
basal body temperature (BBT) rise. Instead of mucus or BBT as indicators, a hormonal marker of
ovulation would be useful. Some home-based ovulation predictor kits based on LH identification in the
urine have been marketed for this purpose [12], [13]. However, in a previous study, it was discovered that
ovulation may sometimes be missed with LH kits if their threshold are above 20 mIU/mL [11].
Furthermore, there are many different amplitudes, configurations, and durations of the LH surge that
might erroneously predict ovulation [14], [15].
A more direct and objective measure to confirm ovulation is the urinary measure of the metabolite of
post ovulatory progesterone. Several authors have suggested that the use of single morning urinary
samples of PDG above a threshold would be a better indicator of ovulation [16], [17], [18]. Even more,
devices using this concept were at one time considered for marketing [19]. However, this approach was
vulnerable to error due to the nature of the assays of urinary PDG and the variability in PDG
concentration thought out the menstrual cycle [20]. Traditionally, PDG concentrations have been
corrected for creatinine to avoid these problems; however, this correction adds a technical difficulty to

develop simple-to-use, home-based-point of care devices. As a result, other methods combining
electronic urinary monitors are being studied to address this problem [21], although they are likely to be
cost prohibitive for many women. Despite the latter looking very promising, it is clear that other more
affordable, easy to use, and versatile methods would be welcomed by FABM users.
The combination of robust markers of ovulation, namely urinary hormones and cervical mucus, could
synergistically improve the identification of the fertile and infertile phases. In the mid-nineteen nineties,
researchers collected information from normally ovulating women regarding daily urinary hormone
measures, recordings of basal body temperature, cervical mucus observations, and serial ovarian
ultrasound in order to study the possibility for a PDG urine hormonal assay [11]. A database of
information was created but due to legal-commercial disclosure agreements, the results regarding the
role of PDG in confirming post-ovulatory infertility were not published until now; this paper will present
these results. In this study we assessed the potential diagnostic qualities of these markers, focusing on
a given urinary PDG concentration threshold to identify the post-ovulatory infertile phase of the cycle.

2. Experimental
2.1. Subjects
This European prospective study was conducted between 1996 and 1997 in eight fertility centers: Aixen-Provence, Dijon, and Lyon (France), Milano and Verona (Italy), Düsseldorf (Germany), Liège
(Belgium), and Madrid (Spain). It included healthy menstruating women aged 18–45 years with
previous menstrual cycles of 24–34 days who had experience recording basal body temperature and
monitoring cervical mucus. However, for the purpose of the current analysis, no women were excluded
based on the duration of the cycle.
Women with a history of infertility, pelvic inflammatory disease, cycle disturbances, disturbed follicular
development, or current hormone therapy were excluded from the study. We also excluded women who
had had gynaecological surgery, a delivery within the last three months, women who were
breastfeeding, and competitive athletes.
The study included 107 women and analyzed an average of three cycles per woman for a total of 326
cycles. The original study that collected the data [11] was approved by the local ethics committee
(Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale de Lyon). All
participants gave their written informed consent. The study procedures were carried out in accordance
with the Ethical Standards for Human Experimentation established by the Declaration of Helsinki.

2.2. Methods
2.2.1. Mucus symptoms
Study participants checked for changes in cervical mucus two or three times daily, recording the
sensation (dry, moist, wet, or slippery) and the consistency (tacky, creamy, or stretchy) of the mucus.
This information allowed for the ability to distinguish between (i) days with no mucus felt or seen; (ii)
days with mucus felt or seen but not having the characteristics of high fertility; and (iii) days with mucus

that felt wet or slippery or that resembled an egg-white and had a stretchy appearance. The last day of
clear, stretchy and/or lubricative mucus discharge was called the peak symptom [9], [22]

2.2.2. Hormone assessments
Assays were carried out on the first morning urine (FMU) with two 10–12 mL aliquots frozen on the day
of collection at −20 °C in tubes containing gentamicin sulphate. On the day of analysis, the aliquots
were thawed in a single laboratory and tested in duplicates for quantitative detection of oestrone-3glucuronide (E1G-ng/mL), pregnanediol-3a-glucuronide (PDG-μg/mL), follicle stimulating hormone
(FSH-mIU/mL), and luteinizing hormone (LH-mIU/mL) using time-resolved fluorometric immunosorbent
assays (Delfia). Each hormonal sample was repeated twice: the relative difference (i.e. CV) was
respectively 5.96%, 10.79%, 8.66% and 7.17% for PDG, FSH, LH and E1G. We cannot provide
detailed information on assay performance except the intra-assay CV’s. This data remains within the
property of the funding company.

2.2.3. Ultrasound scans
The serial transvaginal ovarian ultrasounds (with follicle measurements) started either at the onset of
the fertile cervical mucus or at the detection of the LH surge by the home test. These scans were
carried out every other day until the largest follicle reached 16 mm, then every day until evidence of
ovulation. To note that while there is increasing evidence to indicate that multiple ovarian follicular
waves develop during the human menstrual cycle [22], the evidence always point towards the last wave
being the ovulatory single event of a given cycle [23].The same physician at each centre performed the
scans. The ultrasound-determined day of ovulation (US-DO) was the 24-h period that separated the
sight of a mature follicle on one scan and either of the following on the second scan: (i) a change in the
follicle size, shape, or sonographic density; (ii) follicle rupture; (iii) the presence of an early corpus
luteum; (iv) the presence of free fluid in the cul-de-sac. If a woman missed an ultrasound examination,
the US-DO was the first day after the last pre-ovulatory ultrasound with a follicle ⩾18 mm or the second
day with a follicle <18 mm.

2.3. Measured outcomes
2.3.1. Fertility definitions
The fertile phase was estimated during the pre-ovulatory phase as the period stretching from the first
day of menses to the end of the US-DO. The infertile phase was defined as the day after ovulation day,
up to the following menses.
Positive PDG test was defined as a test result above a defined concentration threshold. A negative
PDG test was defined as a test result below that threshold. Different PDG concentration thresholds in
FMU samples were analyzed for specificity, sensitivity, true negative and true positive cycles. A cycle
with at least one day with a positive PDG test in the fertile phase was classified as a false positive: i.e.
PDG concentration was high despite being during the potentially fertile phase. A cycle with all days with
negative PDG tests in the fertile phase was classified as a true negative: i.e. PDG was appropriately
low during the potentially fertile phase. A cycle with days in the infertile phase with positive PDG tests

was classified as a true positive: i.e. PDG was appropriately high during the infertile phase. A cycle
without at least one day in the infertile phase with a positive PDG test was classified as a false
negative: i.e. PDG was always low despite being in the infertile phase.
The sensitivity was estimated as the proportion of true positives, that is, cycles with appropriate
recognition of the post-ovulatory infertile phase. The specificity was estimated as the proportion of true
negatives, that is, cycles with appropriate recognition of the pre-ovulatory fertile phase. Lack of
specificity creates the risk of unplanned pregnancy, and therefore, a high specificity for ovulation
confirmation was the main aim of the study. Achieving a specificity of 100% would mean that there is no
positive test in the absence of ultrasound-confirmed ovulation, in other words, we would not want a
woman to think she was infertile if she has not yet ovulated.

2.3.2. Tested scenarios for different PDG thresholds
The following scenarios were tested: (A) Use of the daily PDG test alone starting the first day of the
cycle; (B) Use of the daily PDG test only after a first positive urine LH kit result (LH threshold of
20 mIU/mL); and (C) Use of the PDG test only after the disappearance of highly fertile type mucus at
the vulva, i.e. return to absence of mucus or mucus without the characteristics of high fertility. In the
event of a second wave of highly fertile type mucus during the testing, the test was re-started following
the disappearance of the second wave of highly fertile type mucus. The chosen LH threshold of
20 mIU/mL was based on data from previous published analysis [15]. The two most common used
thresholds of commercially available urinary LH kits are 20 and 25. The respective specificity and
sensitivity were found to be 0.95 and 0.43 for a threshold of 20; and, 0.97 and 0.34 for 25. Given on
these results, we chose 20 to be the best as it had the higher sensitivity.

2.3.3. PDG test models and interpretation of the results
We postulated two models of using the PDG test based on current FABM practices: (1) One day of
positivity above a certain threshold is considered to be sufficient to declare infertility; or (2) Three
consecutive days of positivity are observed before infertility is declared.

2.4. Statistical analysis
The best threshold was obtained through secondary analysis by performing a statistical analysis in a
range from 0.5 to 15 μg/mL and determining the threshold based on specificity and sensitivity.
Sensitivity and specificity were estimated with their 95% confidence intervals. Then a ROC (the
Receiver Operating Characteristic) curve was used to describe the evolution of sensitivity and
specificity according to the given threshold. A descriptive analysis of the cycle characteristics was
performed using geometric mean, standard deviation, minimum, median, and maximum for quantitative
data. Frequency was used for categorical variables. All statistical analyses were performed using the R
software version 2.13.0 (The R Foundation for Statistical Computing). A p-value <0.05 was considered
for statistical significance.

3. Results
Table 1 depicts the participants’ characteristics including hormonal profiling. The 107 subjects studied
were 19–44 years old. Sixty-nine of them (64%) had at least one child before the study. The BMIs
ranged between 17.1 and 28.3. Eleven women reported current smoking. The mean cycle length was
28.1 days (range 22–44 days). The mean time to ovulation was 14.8 days (range 9–33 days) and the
mean post-ovulatory phase length was 13.3 days (range 7–17 days). In 28 cycles out of the 326
monitored, the first ultrasound was performed after ovulation and, in 15 others, it was not possible to
determine exactly the day of ovulation by ultrasound. This left 283 ovulatory cycles for analysis. In a
sub-analysis, out of the 206 available cycles with complete records on mucus coding, eight cycles (4%)
showed two waves of fertile-type cervical mucus separated by a vaginal dry phase. Ovulation followed
the last wave. It is well recognized that this is a product of variations in hormonal patterns within the
menstrual cycle [24]. In addition, as previously published [32], no differences were observed between
different BMI groups and PDG mean levels: 12.41(0.56), 13.09 (0.53), 11.70 (0.80) μg/mL for BMI
ranges of <19.2, 19.2–23.4, and >23.4 respectively.

Table 1. Women and cycles characteristics.
Characteristics

Mean (±sem)

Minimum

Maximum

Women
Age (years)
Age at Menarche (years)
Body mass index (kg/m2)
Sport activity (h/week)
Regular smokers (%)
Vegans (%)

32.42 (0.35)
13.17 (0.1)
21.27 (0.15)
1.16 (0.13)
11
4

19
9
17.12
0

44
17
28.34
9

Cycles
Cycle length (days)
Follicular phase (days)
Luteal phase (days)

28.07 (0.17)
14.76 (0.17)
13.35 (0.1)

22
9
7

44
33
17

FSH (mIU/mL)
Early follicular phase
Periovulatory phase
Luteal phase

3.61 (0.19)
5.24 (0.26)
1.73 (0.1)

0.06
0.08
0.06

26.26
21.42
10.75

LH (mIU/mL)
Early follicular phase
Periovulatory phase
Luteal phase

3.56 (0.13)
15.5 (0.66)
6.19 (0.37)

0.08
0.54
0.08

11.77
51.82
52.99

E1–3-G (ng/mL)
Early follicular phase
Periovulatory phase

10.61 (0.34)
50.76 (1.87)

1.17
4.44

45.44
281.18

Characteristics
Luteal phase

Mean (±sem)
29.72 (1.21)

Minimum
2.39

Maximum
213.52

Pd-3α-G (μg/mL)
Early follicular phase
Periovulatory phase
Luteal phase

2.34 (0.09)
3.02 (0.1)
12.66 (0.37)

0.18
0.31
1.53

19.62
14.68
64.84

Average hormonal concentrations were estimated at the three phases of the cycle: at days 2, 3, and 4 of the cycle
for the early follicular phase, at US-DO ± 1 for the periovulatory phase, and at US-DO +5,+7, and +9 for the luteal
phase.

The specificity and sensitivity of the PDG test in a range from 0.5 to 15 μg/mL with all various proposed
scenarios is depicted in the Receiver Operating Characteristic curves in Fig. 1. The main goal of this
study was to achieve a low false positive rate, that is, highest specificity, to ensure the lowest simulated
pregnancy rate and to confirm ovulation. The ideal concentration threshold in a FMU sample for PDG
positivity was found to be at 5 μg/mL.

Fig. 1. ROC curves presenting the evolution of true and false positive rates according to the chosen
threshold of PDG tests; one ROC curve per scenario.
The two scenarios with the highest specificity are Scenario B; using the PDG test for three consecutive
days after a first positive urine LH kit result and Scenario C which is the most specific; using the PDG
test for three consecutive days after high fertility cervical mucus is detected.

Table 2, Table 3 show the number of daily PDG tests used for each of the three scenarios, the number
of recognized true infertile days by the testing, the test’s specificity and sensitivity.

Table 2. Estimated measures of the performance of PDG positivity in the one-day model
(threshold: 5 μg/mL).
Number of daily testing
One positive PDG result
Testing scenarios
Number of
Number of
Sensitivity Specificity
recognized true
days tested
%
%
infertile days
(A) Daily PDG testing alone from day 1 12.1
5.5
0.986
0.534
(B) PDG daily testing only after a
2.3
6.5
0.756
0.776
positive LH test
(C) PDG testing following peak fertility
(i.e. presence of high fertile type mucus
2.8
9.5
0.984
0.907
at the vulva followed by a change to
non-fertile type)

Table 3. Estimated measures of the performance of PDG positivity in the 3-day model
(threshold: 5 μg/mL).

Testing scenarios

Number of daily testing
Three daily consecutive positive PDG results
Number of
Number of
Sensitivity Specificity
recognized true
days tested
%
%
infertile days
18.6
6.6
0.929
0.862

(A) Daily PDG testing alone from day 1
(B) PDG daily testing only after a positive
5.2
LH test
(C) PDG testing following peak fertility (i.e.
presence of high fertile type mucus at the
5.9
vulva followed by a change to non-fertile
type)

6.1

0.721

0.986

7.6

0.922

1

Table 2 shows the results associated with scenarios using the one-day model of positive PDG testing
above a specific threshold. Table 3 refers to the three-day model (three days of consecutive positive
tests). The three scenarios were applied to both models.
The most specific scenario, which combined the use of three positive PDG tests after the identification
of high fertility mucus (Scenario C), resulted in 92% of sensitivity for ovulation. In this scenario, 6 days
were tested per cycle and 7.6 days are recognized as infertile during the post-ovulatory phase. If we
ignore the 8% of cycles with lack of sensitivity, 8.1 days are recognized as infertile during the postovulatory phase.

The other scenarios were all limited in some way. First, when using LH positivity as the starting point for
the PDG test (Scenario B), there was limited sensitivity with only 76% of the cycles achieving a positive
LH test and thus precluding the use the PDG test. Second, when using the PDG test alone (Scenario
A), there was limited specificity and the PDG test occasionally read positive before ovulation had taken
place.
In a sub-analysis to take into account sport activity, data was available for 76 women. We did it to
assess whether sport activity may be associated with a reduced luteal PDG. First, we divided
participants in three groups: no sport-activity, intensive sport-activity for less than 3 h per week and for
more than 3 h per week. The sport activity was assessed only once per woman and we analyzed the
data accordingly. Within each group, PDG values from three days of each cycle were averaged to
obtain one value per cycle (i.e. the mean PDG level of days US-DO +5, +7, and +9). We then averaged
all these mean PDG levels for all the cycles within a given group. In this analysis, the results obtained
were 11.23, 12.01 and 11.14 for the three groups respectively (p = 0.77, i.e. the difference was not
statistically significant).

4. Discussion
The present study predicts that the use of three consecutive days of PDG testing over a threshold of
5 μg/mL in a FMU sample will result in a perfect specificity for ovulation confirmation following fertilitytype mucus identification. The 100% confirmation would allow women to identify the absolute infertile
period after ovulation for the sake of avoiding pregnancy. On the other hand, the rationale behind the
fact that the combination of LH/PDG did not give a perfect specificity can be found on recent LH
research [15]. It is now known that LH levels present some variability in amplitude, duration and
configuration with ovulation sometimes occurring later than one day after the LH surge. It is then
possible that our proposed PDG test protocol may give a false negative since it may test too early to
show a PDG surge. However, we believe the high specificity obtained is still within the clinically relevant
range (Sp = 0.986).
The beginning of the fertile phase still requires the use of a first indicator; either, a count of days from
the onset of the cycle, or the presence of mucus, felt or seen, at the vulva [6] or the detection of a
significant rise in urinary E1G, either alone or in various combinations [25], [26], [27]. To identify the end of
the fertile phase, our results confirm the interest of using either a LH test first or to rely on days
following the presence of cervical mucus for FABM users, and then confirm the infertility using three
consecutive days of PDG testing over a threshold of 5 μg/mL in a FMU sample. A noon sample of
urinary LH above a set threshold has been considered sufficient to identify the imminence of ovulation
[28]
. Alternatively, instead of relying on the same threshold for every woman, electronic devices have
been developed to identify a significant increase over a given woman’s baseline hormonal levels during
the previous days [29]. Our results show that three consecutive days of PDG positivity above a specific
threshold following LH positivity or the end of fertile-type cervical mucus will confirm infertility with a
high predictive specificity.
Clinical an-ovulatory scenarios such as pre-menopause and polycystic ovarian disease (PCOD), has
been mentioned as challenges for FABM use. Firstly, the effect of these scenarios should be negligible

in the interpretation of the PDG method; since, it is only with those ovulatory cycles that the rise of
urinary PDG occurs. However, it is been long reported that there are clinical scenarios when luteal
progesterone levels, and consequently PDG levels as well, may be found at lower level than normal: in
women with unexplained infertility, after ovulation induction with clomiphene citrate or gonadotropins, in
women with hyperprolactinemia, recurrent miscarriages, luteinizing unruptured follicles, in
oligomenorrheic obese women with or without hirsutism such as PCOD, and in perimenopausal women
[30] [31] [32]
, , . Our current proposed protocol lacks the power to discriminate for all these conditions
because it is based on one single threshold, yet, it could be the source of future research on the
relationship between cervical mucus, LH and PDG surges. Secondly and even more importantly, it is
the combination of two markers (cervical mucus or LH) plus PDG that may provide the safety net
needed in these conditions with reduced PDG level. For instance, it is recognized that use of cervical
mucus monitoring in FABM can help to identify approaching ovulation even in pre-menopause [24].
Thirdly, in clinical situations such as vaginal infections when the cervical mucus essentially becomes
non-interpretable, the use of urinary LH testing could be used as substitute as mentioned in our
protocols. Finally, despite the fact that the clinical question of accurately identifying the infertile phase of
the menstrual cycle is an old one (1, 2, and 20), the proposed model is new. No quantitative
assessment of the use of PDG as adjunct to the concurrent use of FABM has ever been published, nor
a study has used such a large dataset.
With these results, the next major challenge will be the development of a simple competitive lateral flow
assay for the detection of PDG in the urine. The ability to develop such assays has been available for
several years and the manufacturing processes of these tests are well known. Similar urinary tests
such as those used to identify commonly abused substances could be adapted for this purpose given
that PDG and these substances have comparable molecular weights [33].
One further theoretical limitation of our study is that the algorithms used were based on multiple cycles
per participants, leading to potentially to overestimates of specificity and sensitivity. To quantify for this
effect, a mixed regression model for repeated measurement was used to describe the PDG level during
the luteal phase (at US-DO +5, +7, and +9). The inter-women and intra-women coefficients of variation
were respectively 30% and 11%. However, we did not use a validation dataset to confirm the sensitivity
and specificity: our estimates of performance can be overly optimistic. It would be wise to confirm these
results using other datasets in future research. This fact might indeed contribute to an overestimate of
specificity, but not necessarily invalidate the results in a clinical setting. Likewise, the fact that our PDG
assays were tested only among European women, it may potentially limits the study’s results yet not
necessarily invalidating our findings [34]. A clinical study based on the proposed PDG devices would
again need to address concerns such a different population and racial differences.
Given that this test has a dual purpose (to confirm the end of the fertile period for women wishing to get
pregnant and identifying the infertile phase for those wishing to avoid pregnancy) it is very versatile.
The 100% specificity for ovulation in these scenarios would be helpful to identify those women with
adequate ovulation for the purpose of an infertility work-up, providing a home-based alternative for
serum progesterone testing. For those wishing to postpone pregnancy, the high specificity for ovulation
demonstrated here provides a simple and very reliable identification for the post-ovulatory infertile
phase. In order to make this approach practical, the cost of the simple PDG test ought to remain low.

Future studies could assess the two best scenarios (B and C) for women who are seeking to avoid and
achieve pregnancy.
On a side note, it was noted that in 2% of the cycles (6/283), menses occurred beyond the generally
accepted 16 days post-ovulation, in these few cycles, we question whether the ultrasound
determination of the day of ovulation was off by one day or two or an early pregnancy loss occurred.
Our assessment of these rare events led us to conclude that the potential bias would not be significant.
In order to provide women with a simple, home-based test to identify the absolute infertile period after
ovulation, we have demonstrated a new objective measure that is 99–100% specific for the ovulation
event as confirmed by ultrasound. In order to avoid the previous challenge of the individual woman’s
menstrual cyclic variations in urinary concentrations of PDG, we have proposed a novel model that
employs three consecutive days of PDG tests above a threshold of 5 μg/mL after either LH positivity or
highly fertile mucus. This model is 99–100% specific for ovulation depending of the scenario used and
is thus a very promising tool for women wanting a conservative and reliable measure to complement
their Fertility Awareness Based Method.
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